Nexiam (Esomeprazole)

Esomeprazole, the active ingredient in Nexiam, is a proton pump inhibitor presented as an oral dosage form for systemic use. It reduces gastric acid production and is prescribed for acid‑related disorders such as gastro‑oesophageal reflux disease and ulcer conditions. The medication is absorbed rapidly, achieving peak plasma concentrations within a few hours, and provides prolonged suppression of gastric acidity, facilitating healing of the esophageal lining and protection of the stomach mucosa.

GNH USA supplies Nexiam as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Esomeprazole is indicated for several acid‑related gastrointestinal conditions. - Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of esophageal irritation. - Erosive esophagitis: accelerates mucosal healing and reduces recurrence of lesions. - NSAID‑induced gastric ulcer: protects the gastric lining and supports ulcer resolution. - Helicobacter pylori eradication (in combination therapy): enhances the effectiveness of antibiotic regimens by reducing gastric acidity.

Common and serious adverse reactions have been reported with esomeprazole use.

Common Side Effects: - Headache: mild to moderate intensity, often transient and not requiring treatment. - Diarrhea: loose, watery stools that usually resolve without medical intervention. - Nausea: occasional feeling of queasiness, sometimes accompanied by a mild stomach upset.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling of face or throat, or difficulty breathing that needs immediate care. - Clostridioides difficile infection: persistent watery diarrhea with abdominal cramping, indicating possible colitis. - Low magnesium levels (hypomagnesemia): muscle cramps, tremor, or irregular heartbeat that may require monitoring.

When prescribing esomeprazole, clinicians should consider several precautionary measures to ensure safe use. - Assess renal function: dose adjustment may be needed in severe renal impairment. - Review concomitant medications: avoid use with drugs that require gastric acidity for absorption. - Monitor long‑term therapy: prolonged use can increase risk of bone fractures and vitamin B12 deficiency. - Evaluate for infection risk: patients with a history of C. difficile should be observed closely. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk, after professional assessment. - Store at ambient temperature: keep below 25 °C in the original packaging, protected from moisture and light.

Esomeprazole may alter the plasma concentrations of several co‑administered drugs.

Major Interactions (Avoid): - Antiretroviral protease inhibitors (e.g., atazanavir): reduced absorption leading to therapeutic failure. - Antifungal agents (e.g., ketoconazole, itraconazole): markedly decreased bioavailability. - Clopidogrel: diminished activation, potentially reducing antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring closer coagulation monitoring. - Digoxin: slight increase in serum levels, may need dose adjustment. - Methotrexate (high dose): reduced renal clearance, monitor for toxicity.